IMPAACT4TB PROJECT OUTPUTS

2021

Accelerate development and filing of RPT
- Scale up of 3HP for PLHIV
- TPT Scale-up in PLHIV and Adult HHC—FDC acceleration with 1st Generic
- Evidence generated for 3HP and scalable models of delivery

2022

NO COST EXTENSION

- Generic Development of Paediatric 3HP Formulation
- 2nd generic filing for 300mg and FDC 3HP
- Validation batches available
- 2nd generic product entry 300mg and FDC 300/300

2023

- TPT Scale-up: FDC acceleration with 1st and 2nd Generic 3HP
- Evidence 1HP vs 3HP and Partnerships for demonstration of 3HP & 1HP delivery with Global Fund/PEPFAR Surge Countries

2024

- Costed Extension
- TPT Scale-up in Children using 150mg film-coated singles and FDC based on current weight banding
- Scale-up 3HP/1HP in Children using preferred Ped Formulation 150mg FS DT

2025

 출력

- Continuation State funded and donor-funding TPT scale

Legend:
- NCE Research
-RESULTS
- DOLPHIN TOO
- RESULTS OF TBTC35
- CAT & CHIP STUDIES END
- INDIA DEMO STUDY
- INTERIM ANALYSIS
- STUDY ENDS
1. Establish a price agreement for RPT with the innovator in the short term and with generic supplier(s) in the long term
2. Accelerate development and filing of RPT with a global level SRA (WHO PQ and/or FDA) and country National Drug Regulatory Agencies (NDRAs), through an incentive grant, by generic supplier(s)
3. Initial scale up of 3HP for PLHIV supported
4. Initial scale up of 3HP for contacts supported
5. Evidence generated and disseminated for optimal use of 3HP and scalable models of delivery (global and country level)
6. Engage with WHO to ensure the successful implementation of the IMPAACT4TB and other Unitaid TB projects

Evidence generated for 3HP & scalable models of delivery